Atreleuton

Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation[1][2][3]. Atreleuton is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

CAS Number

[154355-76-7]

Product Name Alternative

ABT-761; VIA-2291

UNSPSC

12352005

Hazard Statement

H302

Target

Lipoxygenase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/atreleuton.html

Concentration

10mM

Purity

99.0

Solubility

10 mM in DMSO

Smiles

O=C(N)N([C@H](C)C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)O

Molecular Formula

C16H15FN2O2S

Molecular Weight

318.37

Precautions

H302

References & Citations

[1]VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease. VIA Pharmaceuticals, Inc.|[2]Reid JJ, et al. ABT-761 (Abbott) . Curr Opin Investig Drugs. 2001 Jan;2 (1) :68-71.|[3]Bell RL, et al. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther. 1997 Mar;280 (3) :1366-73.